688526 科前生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.79810.2389.83310.79912.316
总资产报酬率 ROA (%)2.4889.0198.3428.73810.092
投入资产回报率 ROIC (%)2.6659.7479.0199.52111.172

边际利润分析
销售毛利率 (%)59.42266.97363.75672.09373.611
营业利润率 (%)34.61250.86846.59143.14846.612
息税前利润/营业总收入 (%)29.42644.68539.97736.76840.267
净利润/营业总收入 (%)30.68943.90040.50137.17640.863

收益指标分析
经营活动净收益/利润总额(%)82.33188.33589.957112.82199.502
价值变动净收益/利润总额(%)17.7578.4478.5822.0411.735
营业外收支净额/利润总额(%)-0.507-0.327-0.163-0.339-0.023

偿债能力分析
流动比率 (X)7.8226.3985.3363.3844.105
速动比率 (X)7.4446.0835.0653.1933.834
资产负债率 (%)10.68211.48512.29617.84520.307
带息债务/全部投入资本 (%)2.6542.5712.7979.7289.042
股东权益/带息债务 (%)3,583.9383,707.9163,398.015910.127970.482
股东权益/负债合计 (%)836.299770.650712.912460.132392.198
利息保障倍数 (X)-5.871-7.425-6.115-5.897-6.356

营运能力分析
应收账款周转天数 (天)135.142117.489127.304110.821106.339
存货周转天数 (天)172.296154.864142.568190.461189.534